Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracheobronchial adenoid cystic carcinoma mimicking bronchial asthma.

Journal of postgraduate medicine·2022
Same author

Clinical approaches towards asthma and chronic obstructive pulmonary disease based on the heterogeneity of disease pathogenesis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Developments in the field of allergy in 2014 through the eyes of Clinical and Experimental Allergy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Genomewide association study identifies HAS2 as a novel susceptibility gene for adult asthma in a Japanese population.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2014
Same author

The search for genetic links in NSAID-induced acute urticaria and the arachidonic acid pathway.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2012
Same author

Variants in the 17q21 asthma susceptibility locus are associated with allergic rhinitis in the Japanese population.

Allergy·2012

Related Experiment Video

Updated: Jun 16, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Beta-2 adrenergic receptor genetic polymorphisms and asthma.

N Hizawa1

  • 1Department of Pulmonary Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba 305 8575, Japan. nhizawa@md.tsukuba.ac.jp

Journal of Clinical Pharmacy and Therapeutics
|February 24, 2010
PubMed
Summary

Genetic variations in the Beta-2-Adrenergic receptor (beta(2)AR) gene may not cause asthma but could influence its severity and response to beta(2)-agonist treatments, aiding personalized asthma management.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenomics
  • Respiratory Medicine
  • Molecular Biology

Background:

  • Beta-2-Adrenergic receptors (beta(2)AR) are crucial for lung physiology, regulating bronchodilation and protective mechanisms.
  • These receptors are implicated in asthma pathophysiology, making their genetic variations a focus of research.
  • The ADRB2 gene, encoding beta(2)AR, is highly polymorphic, suggesting a role in individual responses.

Purpose of the Study:

  • To review the association between ADRB2 gene polymorphisms and asthma.
  • To explore the impact of these polymorphisms on asthma-related phenotypes and bronchodilator responses.
  • To assess the potential of ADRB2 genotyping for predicting asthma outcomes and treatment responsiveness.

Main Methods:

  • Systematic review of studies investigating ADRB2 polymorphisms and asthma.
  • Analysis of genotype-phenotype correlations, including asthma severity and response to beta(2)-agonists.
  • Evaluation of existing literature on the clinical utility of ADRB2 genotyping.

Main Results:

  • Current evidence suggests ADRB2 polymorphisms are not directly causative of asthma.
  • However, specific polymorphisms may influence asthma disease severity and patient response to beta(2)-agonist therapy.
  • Genotyping may offer predictive value for asthma progression and chronic treatment efficacy.

Conclusions:

  • ADRB2 polymorphisms appear to modulate asthma phenotypes and treatment responses rather than causing the disease.
  • Future research and well-powered clinical trials are essential to validate the predictive role of ADRB2 genotype in asthma management.
  • Personalized medicine approaches incorporating pharmacogenomics could optimize asthma care.